Compare Global X Data Center & Digital Infra ETF (DTCR) vs Halozyme Therapeutics Inc. Common Stock (HALO) Price & Performance

Global X Data Center & Digital Infra ETFTrade

Halozyme Therapeutics Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Global X Data Center & Digital Infra ETF vs Halozyme Therapeutics Inc. Common Stock — how do they compare? Global X Data Center & Digital Infra ETF trades at $27.65 (market cap $2.04B), while Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 6.2× Global X Data Center & Digital Infra ETF's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Global X Data Center & Digital Infra ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Data Center & Digital Infra ETF for 15 Days and Halozyme Therapeutics Inc. Common Stock for 1 Days on average.

	DTCR	HALO
Market Cap	$2.04B	$12.58B
Volume	899,532	2,179,278
Sector	Sector/Thematic	Health
52-Week High	$32.46	$115.22
52-Week Low	$19.73	$61.63
Typical Hold Time	15 Days	1 Days
Enterprise Value	—	$14.49B

View details →View details →

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DTCR

100% Buy0% Sell

Avg holding period · 15 Days

HALO

No sentiment data available yet.

Top news

Latest headlines on both assets

DTCR

Data center builders IREN, TeraWulf, and Core Scientific fall sharply due to rising borrowing costs.24/7 Wall Street · 2 days agoBearish Applied Digital rises 3% on Finland power deal opening 1 GW data center capacity ahead of earnings.24/7 Wall Street · 3 days agoBullish View details →

HALO

View details →

About Global X Data Center & Digital Infra ETF

Global X Data Center & Digital Infrastructure ETF seeks exposure to companies involved in data centers and digital infrastructure. Its holdings span areas such as digital infrastructure, networking, and related real estate.

About Halozyme Therapeutics Inc. Common Stock

Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.